Biolojic Design, Ltd. news
Eli Lilly and Company (NYSE: LLY) and Biolojic Design Ltd. ("Biolojic"), a biotechnology company that computationally designs functional antibodies, today announced a research collaboration and license agreement that will leverage Biolojic`s AI-based multibody platform to discover and develop a potential novel antibody-based therapy for the treatment of diabetes.
A multi-specific antibody, or multibody, is a human antibody that is computationally engineered to bind two or more targets
Biolojic Design (“Biolojic”), a biotechnology company that computationally designs functional antibodies, today announced that it has entered into a research collaboration and license option agreement with Nektar Therapeutics to discover and develop agonistic antibodies that activate a novel and previously un-drugged target for the treatment of autoimmune disease. Financial terms of the transaction were not disclosed.
“Our AI-based platform designs mono- and multi-sp
- Biolojic uses its proprietary AI platform to design antibodies with new capabilities to cure disease, ushering in a new era of smart therapeutics
- Biolojic Tel Aviv to focus on computational design of antibodies; Boston location will focus on drug development
Biolojic Design, a unique technology company pioneering computational design of human antibodies to develop smart therapeutic solutions for multiple diseases using advanced AI technology and validated biol